Cleveland BioLabs Profit Margin

The latest profit margin for CBLI is -6043.51% as of June 2021. That compares with -246.62% in the prior-year period — down 2350.5% year over year. That is below the Healthcare sector average of 9.48%. Investors often review this figure alongside Cleveland BioLabs's historical trend and sector peers before judging valuation or financial health.

Over the past year, CBLI's profit margin moved from -246.62% to -6043.51% — a 2350.5% year-over-year decrease. If the trend continues in the same direction for several quarters, it can signal a meaningful shift in Cleveland BioLabs's valuation or profitability profile.

Against Healthcare companies, CBLI currently prints -6043.51% for profit margin, while the sector average sits near 9.48%. That is roughly 63843.7% below the sector mean. Large gaps often invite a closer look at Cleveland BioLabs's growth, margins, and balance sheet.

Profit Margin shows how effectively Cleveland BioLabs converts resources into returns. At -6043.51%, CBLI may look efficient or underperforming depending on peer benchmarks and trend direction. That compares with -246.62% in the prior-year period — down 2350.5% year over year. Pair the percentage with revenue growth and leverage for a fuller health check.

After noting CBLI's profit margin (-6043.51%), review year-over-year change from -246.62%, peer averages, and a few neighboring metrics such as revenue, margins, or valuation multiples. That combination usually beats staring at a single figure. The navigation links on this page jump you to those related views.